SEC Filing Summary: Galena Biopharma, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Galena Biopharma, Inc. on December 1, 2016, reporting an event that occurred on November 29, 2016. The filing addresses the company's compliance status with the Nasdaq Stock Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance regarding stock listing requirements.
Material Changes
The primary material event is the resolution of a listing deficiency. Galena Biopharma received notice from Nasdaq that it has regained compliance with Listing Rule 5450(a)(1). This compliance was achieved because the company's common stock closed at or above $1.00 per share for ten consecutive trading days prior to the notice date. Nasdaq has indicated that this matter is now closed.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of new risks or contingencies beyond the resolution of the specific listing issue.
Key Facts for Investor Verification
- Galena Biopharma has successfully regained compliance with Nasdaq's minimum bid price requirement.
- The stock price sustained a closing value of at least $1.00 for ten consecutive trading days ending prior to November 29, 2016.
- The Nasdaq Listing Qualifications Department has officially closed the compliance matter.
- Note: The request metadata referenced "SELLAS Life Sciences Group, Inc.," but the filing text explicitly identifies the registrant as "Galena Biopharma, Inc."